This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Biosimilars In Emerging Economies - Advanced Recombinant Technology Platforms And Low Cost Manufacturing Put India And China At A Strategic Advantage In Biosimilar Production

Table 16: Biosimilars in Emerging Economies, Pipeline Molecules, Lupin, 2012 39

Table 17: Biosimilars in Emerging Economies, Pipeline Molecules, Cipla, 2012 40

Table 18: Biosimilars in Emerging Economies, China, Revenue ($bn), 2002–2011 41

Table 19: Biosimilars in Emerging Economies, China, Revenue Forecasts ($bn), 2011–2018 41

Table 20: Biosimilars in Emerging Economies, Marketed Biosimilar Products, China, 2012 42

Table 21: Biosimilars in Emerging Economies, Marketed Biosimilar Products, 3SBio, 2012 43

Table 22: Biosimilars in Emerging Economies, Pipeline Molecules, 3SBio, 2012 44

Table 23: Biosimilars in Emerging Economies, Marketed Biosimilar Products, CPGJ, 2012 45

Table 24: Biosimilars in Emerging Economies, Pipeline Molecules, CPGJ, 2012 45

Table 25: Biosimilars in Emerging Economies, Marketed Biosimilar Products, Biotech Pharma, 2012 46

Table 26: Biosimilars in Emerging Economies, Pipeline Molecules, Filed, 2011 60

Table 27: Biosimilars in Emerging Economies, Pipeline Molecules, Phase III, 2011 60

Table 28: Biosimilars in Emerging Economies, Pipeline Molecules, Phase II, 2011 62

Table 29: Biosimilars in Emerging Economies, Pipeline Molecules, Phase I, 2011 62

Table 30: Biosimilars in Emerging Economies, Pipeline Molecules, Pre-clinical, 2011 63

Table 31: Biosimilars in Emerging Economies, Pipeline Molecules, Discovery, 2011 65

Table 32: Biosimilars in Emerging Economies, Pipeline Molecules, IND Filed, 2011 66

Table 33: Biosimilars in Emerging Economies, Pipeline Molecules, Unknown Phase, 2011 66

Table 34: Biosimilars in Emerging Economies, M&A by Year, 2007–2011 74

Table 35: Biosimilars in Emerging Economies, M&A by Value ($m), 2007–2011 75

Table 36: Biosimilars in Emerging Economies, M&A Deals, 2007–2011 76

Table 37: Biosimilars in Emerging Economies, Licensing Agreements, 2007–2011 78

Table 38: Biosimilars in Emerging Economies, Co-developments, 2007–2011 80

 

 

 

List of Figures

 

Figure 1: Biosimilars in Emerging Economies, EPO Biosimilars Marketed Outside the US and EU, 2011 12

Figure 2: Biosimilars in Emerging Economies, G-CSF Biosimilars Marketed Outside the US and EU, 2011 13

6 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs